Discovery of novel src homology region 2 domain‐containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma

Wei‐Tien Tai, Chung‐Wai Shiau, Pei‐Jer Chen, Pei‐Yi Chu, Hsiang‐Po Huang, Chun‐Yu Liu, Jui‐Wen Huang, Kuen‐Feng Chen – 2 August 2013 – Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma (HCC). Here, we report that Src homology region 2 (SH2) domain‐containing phosphatase 1 (SHP‐1) is a major target of sorafenib and generates a series of sorafenib derivatives to search for potent SHP‐1 agonists that may act as better anti‐HCC agents than sorafenib.

Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study

Michael W. Fried, Maria Buti, Gregory J. Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele Smedt, Maria Beumont‐Mauviel – 2 August 2013 – The phase IIb, double‐blind, placebo‐controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once‐daily (QD) with pegylated interferon (Peg‐IFN)‐α‐2a and ribavirin (RBV) in treatment‐naïve patients with HCV genotype 1 infection.

Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study

Michael W. Fried, Maria Buti, Gregory J. Dore, Robert Flisiak, Peter Ferenci, Ira Jacobson, Patrick Marcellin, Michael Manns, Igor Nikitin, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele Smedt, Maria Beumont‐Mauviel – 2 August 2013 – The phase IIb, double‐blind, placebo‐controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once‐daily (QD) with pegylated interferon (Peg‐IFN)‐α‐2a and ribavirin (RBV) in treatment‐naïve patients with HCV genotype 1 infection.

The role of macrophage migration inhibitory factor in autoimmune liver disease

David N. Assis, Lin Leng, Xin Du, Clarence K. Zhang, Gerrit Grieb, Melanie Merk, Alvaro Baeza Garcia, Catherine McCrann, Julius Chapiro, Andreas Meinhardt, Yuka Mizue, David J. Nikolic‐Paterson, Jürgen Bernhagen, Marshall M. Kaplan, Hongyu Zhao, James L. Boyer, Richard Bucala – 2 August 2013 – The role of the cytokine, macrophage migration inhibitory factor (MIF), and its receptor, CD74, was assessed in autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC).

Kinetic differences in the induction of interferon stimulated genes by interferon‐α and interleukin 28B are altered by infection with hepatitis C virus

Nikolaus Jilg, Wenyu Lin, Jian Hong, Esperance A. Schaefer, David Wolski, James Meixong, Kaku Goto, Cynthia Brisac, Pattranuch Chusri, Dahlene N. Fusco, Stephane Chevaliez, Jay Luther, Kattareeya Kumthip, Thomas J. Urban, Lee F. Peng, Georg M. Lauer, Raymond T. Chung – 1 August 2013 – Several genome‐wide association studies (GWAS) have identified a genetic polymorphism associated with the gene locus for interleukin 28B (IL28B), a type III interferon (IFN), as a major predictor of clinical outcome in hepatitis C.

Nanoparticles encapsulating hepatitis B virus cytosine‐phosphate‐guanosine induce therapeutic immunity against HBV infection

Shujuan Lv, Jun Wang, Shuang Dou, Xianzhu Yang, Xiang Ni, Rui Sun, Zhigang Tian, Haiming Wei – 1 August 2013 – Infection with hepatitis B virus (HBV) is the most common cause of liver disease worldwide. However, because the current interferon (IFN)‐based treatments have toxic side effects and marginal efficacy, improved antivirals are essential.

Subscribe to